2025/11/19
WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry. This marks the ninth consecutive year that WuXi AppTec has received this distinguished honor, underscoring the company’s ongoing achievements in enabling innovation and operational excellence for its customers.
Read more2025/10/28
Shanghai, October 28, 2025 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH).
Read more2025/10/26
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, and Hillhouse Investment Management (“Hillhouse”), one of the world’s leading global private alternative asset managers, announced that they have reached an agreement for Hillhouse to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO)
Read more2025/10/26
(SHANGHAI, October 26, 2025) – WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 (“Reporting Period”):
Read more2025/10/26
WuXi AppTec Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner
Read more